- Home
- SNDX vs PCT Comparison
SNDX vs PCT Comparison
Compare SNDX & PCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- PCT
- Stock Information
- Founded
- SNDX 2005
- PCT 2015
- Country
- SNDX United States
- PCT United States
- Employees
- SNDX N/A
- PCT N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- PCT Environmental Services
- Sector
- SNDX Health Care
- PCT Utilities
- Exchange
- SNDX Nasdaq
- PCT Nasdaq
- Market Cap
- SNDX 974.9M
- PCT 1.1B
- IPO Year
- SNDX 2016
- PCT N/A
- Fundamental
- Price
- SNDX $11.54
- PCT $5.99
- Analyst Decision
- SNDX Strong Buy
- PCT Strong Buy
- Analyst Count
- SNDX 10
- PCT 4
- Target Price
- SNDX $36.20
- PCT $12.50
- AVG Volume (30 Days)
- SNDX 1.9M
- PCT 2.6M
- Earning Date
- SNDX 05-07-2025
- PCT 05-06-2025
- Dividend Yield
- SNDX N/A
- PCT N/A
- EPS Growth
- SNDX N/A
- PCT N/A
- EPS
- SNDX N/A
- PCT N/A
- Revenue
- SNDX $23,680,000.00
- PCT N/A
- Revenue This Year
- SNDX $286.51
- PCT N/A
- Revenue Next Year
- SNDX $120.86
- PCT $26.46
- P/E Ratio
- SNDX N/A
- PCT N/A
- Revenue Growth
- SNDX N/A
- PCT N/A
- 52 Week Low
- SNDX $9.66
- PCT $4.50
- 52 Week High
- SNDX $25.07
- PCT $15.58
- Technical
- Relative Strength Index (RSI)
- SNDX 44.37
- PCT 38.86
- Support Level
- SNDX $9.66
- PCT $5.90
- Resistance Level
- SNDX $11.61
- PCT $6.66
- Average True Range (ATR)
- SNDX 1.01
- PCT 0.71
- MACD
- SNDX 0.02
- PCT 0.02
- Stochastic Oscillator
- SNDX 56.12
- PCT 29.14
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About PCT PureCycle Technologies Inc. Common stock
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.